Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eisai Inc
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Dacarbazine versus Dacarbazine Alone as First Line Therapy in Patients with Stage IV Melanoma
• Phase Ib: to define the safety, tolerability and maximum tolerated dose (MTD) of E7080 administered in combination with dacarbazine in patients with Stage IV melanoma. • Phase II: to evaluate the ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Thromboembolism
The primary objective of the study is to determine the rate of major bleeing events in cancer patients receiving extended treatment with dalteparin ( more than 6 months and up to 12 months) for preven...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
A study comparing the combination of the best supportive care plus E7080 versus best supportive care alone, in patients with advanced lung cancer or lung cancer that has spread, who have been previously treated, unsuccessfully, with at least 2 different treatments
Compare the overall survival (OS) of patients receiving E7080 + BSC with those receiving placebo + best supportive care (BSC)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Inc
Update Il y a 4 ans
Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia
To compare the overall survival in patients 65 years and older who have newly diagnosed de novo or secondary Acute Myloid Leukemia and either poor or intermediate risk cytogenetics who are randomly as...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Eisai Inc
Update Il y a 4 ans
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer by CA125
• Phase Ib: to define the maximum tolerated dose (MTD)/ recommended Phase II of E7080 administered in combination with carboplatin + gemcitabine in patients with platinum-sensitive recurrent ovarian ...
Country
None
organs
None
Specialty
None
Closed trial
More information